Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer—a narrative review
Open accessThe DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Abstract
Over the last two decades, there has been significant progress in the treatment of metastatic prostate cancer. Multiple treatments with diverse mechanisms of action have improved clinical outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC) including taxane chemotherapy, immunotherapy, potent androgen receptor pathway inhibitors (ARPI), and radiopharmaceuticals (radium-223). As these treatments have entered standard clinical practise, clinicians have been challenged on how to optimally select and sequence them as the landmark studies establishing their efficacy had control arms with placebo or minimally effective therapy and there is a paucity of prospective trials examining treatment sequencing. More recently, the situation has been further complicated as the earlier up-front use of docetaxel and ARPI with standard gonadal testosterone inhibition has been shown to impart substantial improvements in disease control and survival for patients with castration sensitive prostate cancer. As new therapies enter into clinical practise such as the inhibitors of Poly (ADP-Ribose) Polymerase and Prostate Specific Membrane Antigen (PSMA)-targeted therapy, how to optimally select and sequence available treatments will be a continued dilemma in the absence of validated predictive biomarkers. This review will summarize the literature supporting the use of each active agent in mCRPC. We will propose a framework which will guide the selection of appropriate agents based on prior therapies, disease characteristics and biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Generally, selecting treatments with a novel MoA reduces cross-resistance and improves the likelihood of clinical benefit, with the exception of taxane-based chemotherapy [41].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Self-citationAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 3×
“An important consideration is that the main phase III trials of AAP and enzalutamide accrued patients with absent to mild pain, inherently a better-prognosis population, and extrapolation of this data to higher risk patients should be done with caution (7,11,12,49).”
BackgroundSelf-citationIntegrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408 · cited 1×
“Lastly, the alpha-particle emitting radiopharmaceutical Radium-223, also prolongs survival in patients with predominantly bony metastases (14).”
Backgroundde Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318 · cited 1×
“Cabazitaxel, is a taxane chemotherapy with proven activity in patients who have progressed both on ARPI as well as docetaxel with a demonstrated survival benefit both after one or two lines of therapy (13).”
BackgroundEnzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028 · cited 1×
“This class of agents is among the most effective and well tolerated for CRPC (7-9,19-22).”
BackgroundChemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, C. J., Chen, Y.-H., Carducci, M., Liu, G., Jarrard, D. F., Eisenberger, M., Wong, Y.-N., Hahn, N., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,896
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710 · cited 1×
“Studies comparing the response to ARPIs in AR-V7(+) and AR-V7(–) mCRPC patients suggest improved response among men with ARV7(–) mCRPC (76-78).”
Olaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323 · cited 2×
“Notably, the Poly (ADP-Ribose) Polymerase (PARP) inhibitors have promising activity in tumours with genomic defects affecting double-stranded DNA repair by homologous-recombination, with olaparib (16) and rucaparib (28) now granted FDA approval and niraparib (29) which has been granted breakthrough therapy designation.”
BackgroundMethodSelf-citationAbiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704174 · Cited by 2,308
Self-citationDNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185 · cited 1×
“Phase I/II (65,66) studies demonstrated that the identification of a germline or somatic defect in homologous recombination repair (HRR)genes, a subset of genes involved in DDR, particularly BRCA2 alterations, are predictive for a response to the PARP inhibitor, olaparib.”
BackgroundJames, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., Ritchie, A. W. S., Parker, C. C., Russell, J. M., Attard, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01037-5 · Cited by 1,978
Abiraterone for prostate cancer not previously treated with hormone therapy
James, N. D., de Bono, J. S., Spears, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Ritchie, A. W. S., Amos, C. L., Gilson, C., Jones, R. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702900 · Cited by 1,801 · cited 1×
“Indeed, consecutive phase III randomized placebo-controlled trials of docetaxel (21,22) and AAP (23,24) combined with ADT demonstrated a substantial delay in disease progression and improvement in overall survival, compared with upfront ADT alone.”
BackgroundEnzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W. E., Horvath, L. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903835 · Cited by 1,633 · cited 1×
“Recent phase III randomized trials of enzalutamide (25,26) and apalutamide (27), have shown these agents to be similarly efficacious for metastatic castration-sensitive disease.”
BackgroundSelf-citationApalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Chi, K. N., Agarwal, N., Bjartell, A., Chung, B. H., Pereira de Santana Gomes, A. J., Given, R., Juárez Soto, Á., Merseburger, A. S., Özgüroğlu, M., Uemura, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903307 · Cited by 1,564
Self-citationEmerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536
HUGGINS, C. (1941) · Archives of Surgery · doi:10.1001/archsurg.1941.01210140043004 · Cited by 1,499
Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy
Alix-Panabières, C., & Pantel, K. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1483 · Cited by 1,394
Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369 · cited 2×
“An important consideration is that the main phase III trials of AAP and enzalutamide accrued patients with absent to mild pain, inherently a better-prognosis population, and extrapolation of this data to higher risk patients should be done with caution (7,11,12,49).”
BackgroundApalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Smith, M. R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J. N., Olmos, D., Mainwaring, P. N., Lee, J. Y., Uemura, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715546 · Cited by 1,344 · cited 2×
“Furthermore, enzalutamide, apalutamide and darolutamide, novel AR inhibitors, are now indicated for use for patients who transition through a nonmetastatic castration-resistant disease state (19,20,56).”
BackgroundHofman, M. S., Violet, J., Hicks, R. J., Ferdinandus, J., Thang, S. P., Akhurst, T., Iravani, A., Kong, G., Ravi Kumar, A., Murphy, D. G., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30198-0 · Cited by 1,174
Berthold, D. R., Pond, G. R., Soban, F., de Wit, R., Eisenberger, M., & Tannock, I. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4008 · Cited by 1,145
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Hussain, M., Fizazi, K., Saad, F., Rathenborg, P., Shore, N., Ferreira, U., Ivashchenko, P., Demirhan, E., Modelska, K., Phung, D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800536 · Cited by 1,035
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815671 · Cited by 930 · cited 2×
“Furthermore, enzalutamide, apalutamide and darolutamide, novel AR inhibitors, are now indicated for use for patients who transition through a nonmetastatic castration-resistant disease state (19,20,56).”
BackgroundSurvival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022485 · Cited by 792 · cited 1×
“Cohort A derived the greatest survival benefit from olaparib, particularly patients with BRCA2 alterations, while there was no significant survival benefit in cohort B or the entire cohort, even after adjusting for crossover (17).”
BackgroundSelf-citationAbida, W., Patnaik, A., Campbell, D., Shapiro, J., Bryce, A. H., McDermott, R., Sautois, B., Vogelzang, N. J., Bambury, R. M., Voog, E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01035 · Cited by 694
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
de Wit, R., de Bono, J., Sternberg, C. N., Fizazi, K., Tombal, B., Wülfing, C., Kramer, G., Eymard, J.-C., Bamias, A., Carles, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911206 · Cited by 663
Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B. H., Clarke, N., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.06.002 · Cited by 642
Mateo, J., Porta, N., Bianchini, D., McGovern, U., Elliott, T., Jones, R., Syndikus, I., Ralph, C., Jain, S., Varughese, M., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30684-9 · Cited by 634
Abida, W., Armenia, J., Gopalan, A., Brennan, R., Walsh, M., Barron, D., Danila, D., Rathkopf, D., Morris, M., Slovin, S., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00029 · Cited by 541
Annala, M., Vandekerkhove, G., Khalaf, D., Taavitsainen, S., Beja, K., Warner, E. W., Sunderland, K., Kollmannsberger, C., Eigl, B. J., Finch, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0937 · Cited by 515
Self-citationPlatinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
Aparicio, A. M., Harzstark, A. L., Corn, P. G., Wen, S., Araujo, J. C., Tu, S.-M., Pagliaro, L. C., Kim, J., Millikan, R. E., Ryan, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3791 · Cited by 479
Azad, A. A., Volik, S. V., Wyatt, A. W., Haegert, A., Le Bihan, S., Bell, R. H., Anderson, S. A., McConeghy, B., Shukin, R., Bazov, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2666 · Cited by 478
Self-citationDarshan, M. S., Loftus, M. S., Thadani-Mulero, M., Levy, B. P., Escuin, D., Zhou, X. K., Gjyrezi, A., Chanel-Vos, C., Shen, R., Tagawa, S. T., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1417 · Cited by 432
Beer, T. M., Armstrong, A. J., Rathkopf, D., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Evans, C. P., Kim, C.-S., Kimura, G., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.07.032 · Cited by 424
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
Sharp, A., Coleman, I., Yuan, W., Sprenger, C., Dolling, D., Rodrigues, D. N., Russo, J. W., Figueiredo, I., Bertan, C., Seed, G., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122819 · Cited by 393
Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R. G., Chi, K. N., Clarke, N., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.01.012 · Cited by 389
Self-citationCastro, E., Romero-Laorden, N., del Pozo, A., Lozano, R., Medina, A., Puente, J., Piulats, J. M., Lorente, D., Saez, M. I., Morales-Barrera, R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00358 · Cited by 377
Armstrong, A. J., Halabi, S., Luo, J., Nanus, D. M., Giannakakou, P., Szmulewitz, R. Z., Danila, D. C., Healy, P., Anand, M., Rothwell, C. J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01731 · Cited by 362
Khalaf, D. J., Annala, M., Taavitsainen, S., Finch, D. L., Oja, C., Vergidis, J., Zulfiqar, M., Sunderland, K., Azad, A. A., Kollmannsberger, C. K., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30688-6 · Cited by 360
Self-citationLoriot, Y., Bianchini, D., Ileana, E., Sandhu, S., Patrikidou, A., Pezaro, C., Albiges, L., Attard, G., Fizazi, K., De Bono, J. S., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt136 · Cited by 357
Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
Zhu, M.-L., Horbinski, C. M., Garzotto, M., Qian, D. Z., Beer, T. M., & Kyprianou, N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0585 · Cited by 352
Noonan, K. L., North, S., Bitting, R. L., Armstrong, A. J., Ellard, S. L., & Chi, K. N. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt138 · Cited by 343 · cited 1×
“These results are supported by similar outcomes in smaller, retrospective or single arm design trials showing lack of significant activity of AAP post enzalutamide (34,36,37) and modest activity of enzalutamide post AAP (38).”
ResultSelf-citationAparicio, A. M., Shen, L., Tapia, E. L. N., Lu, J.-F., Chen, H.-C., Zhang, J., Wu, G., Wang, X., Troncoso, P., Corn, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1259 · Cited by 295
Nyquist, M. D., Corella, A., Coleman, I., De Sarkar, N., Kaipainen, A., Ha, G., Gulati, R., Ang, L., Chatterjee, P., Lucas, J., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107669 · Cited by 292
Hamid, A. A., Gray, K. P., Shaw, G., MacConaill, L. E., Evan, C., Bernard, B., Loda, M., Corcoran, N. M., Van Allen, E. M., Choudhury, A. D., et al. (2019) · European Urology · doi:10.1016/j.eururo.2018.11.045 · Cited by 274
Mezynski, J., Pezaro, C., Bianchini, D., Zivi, A., Sandhu, S., Thompson, E., Hunt, J., Sheridan, E., Baikady, B., Sarvadikar, A., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds119 · Cited by 246
Hussain, M., Daignault-Newton, S., Twardowski, P. W., Albany, C., Stein, M. N., Kunju, L. P., Siddiqui, J., Wu, Y.-M., Robinson, D., Lonigro, R. J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.7310 · Cited by 206
van Soest, R. J., van Royen, M. E., de Morrée, E. S., Moll, J. M., Teubel, W., Wiemer, E. A. C., Mathijssen, R. H. J., de Wit, R., & van Weerden, W. M. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.09.026 · Cited by 205
Importance of continued testicular suppression in hormone-refractory prostate cancer.
Taylor, C. D., Elson, P., & Trump, D. L. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2167 · Cited by 188
Antonarakis, E. S., Lu, C., Luber, B., Liang, C., Wang, H., Chen, Y., Silberstein, J. L., Piana, D., Lai, Z., Chen, Y., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.01.035 · Cited by 179
De Laere, B., Oeyen, S., Mayrhofer, M., Whitington, T., van Dam, P.-J., Van Oyen, P., Ghysel, C., Ampe, J., Ost, P., Demey, W., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1943 · Cited by 174
Attard, G., Borre, M., Gurney, H., Loriot, Y., Andresen-Daniil, C., Kalleda, R., Pham, T., Taplin, M.-E., & collaborators, O. B. O. T. P. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.9827 · Cited by 173
European cancer mortality predictions for the year 2020 with a focus on prostate cancer
Carioli, G., Bertuccio, P., Boffetta, P., Levi, F., La Vecchia, C., Negri, E., & Malvezzi, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.009 · Cited by 171
Armstrong, A. J., Lin, P., Tombal, B., Saad, F., Higano, C. S., Joshua, A. M., Parli, T., Rosbrook, B., van Os, S., & Beer, T. M. (2020) · European Urology · doi:10.1016/j.eururo.2020.04.061 · Cited by 168
Chi, K. N., Kheoh, T., Ryan, C. J., Molina, A., Bellmunt, J., Vogelzang, N. J., Rathkopf, D. E., Fizazi, K., Kantoff, P. W., Li, J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv594 · Cited by 167
Self-citationBarber, T. W., Singh, A., Kulkarni, H. R., Niepsch, K., Billah, B., & Baum, R. P. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.216820 · Cited by 132
Gillessen, S., Armstrong, A., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R. G., Bulbul, M., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.04.002 · Cited by 130
Self-citationTreatment of mCRPC in the AR-axis-targeted therapy-resistant state
Chi, K. N., Hotte, S. J., Joshua, A. M., North, S. A., Wyatt, A. W., Collins, L. L., & Saad, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv267 · Cited by 123
Self-citationMateo, J., Cheng, H. H., Beltran, H., Dolling, D., Xu, W., Pritchard, C. C., Mossop, H., Rescigno, P., Perez-Lopez, R., Sailer, V., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.01.010 · Cited by 122
de Bono, J. S., Chowdhury, S., Feyerabend, S., Elliott, T., Grande, E., Melhem-Bertrandt, A., Baron, B., Hirmand, M., Werbrouck, P., & Fizazi, K. (2018) · European Urology · doi:10.1016/j.eururo.2017.07.035 · Cited by 119
Eymard, J., Oudard, S. M., Gravis, G., Ferrero, J.-M., Théodore, C., Joly, F., Priou, F., Krakowski, I., Zannetti, A., Thill, L., et al. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09296.x · Cited by 103
Moreira, R. B., Debiasi, M., Francini, E., Nuzzo, P. V., de Velasco, G., Maluf, F. C., Fay, A. P., Bellmunt, J., Choueiri, T. K., & Schutz, F. A. B. (2017) · Oncotarget · doi:10.18632/oncotarget.20028 · Cited by 95
Smith, M. R., Sandhu, S. K., Kelly, W. K., Scher, H. I., Efstathiou, E., Lara, P. N., Yu, E. Y., George, D. J., Chi, K. N., Saad, F., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.043 · Cited by 93
Self-citationBerthold, D., Pond, G. R., deWit, R., Eisenberger, M., & Tannock, I. F. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.5005 · Cited by 90
Lorenzo, G. D., Buonerba, C., Faiella, A., Rescigno, P., Rizzo, M., Riccardo Autorino, B., Perdonà, S., Riccardi, F., Scagliorini, S., Scognamiglio, F., et al. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09498.x · Cited by 88
Loriot, Y., Massard, C., Gross‐Goupil, M., Palma, M. D., Escudier, B. J., Bossi, A., Chauchereau, A., & Fizazi, K. S. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.04.010 · Cited by 87
Khalaf, D. J., Sunderland, K., Eigl, B. J., Kollmannsberger, C., Ivanov, N., Finch, D. L., Oja, C. D., Vergidis, J., Zulfiqar, M., Gleave, M. E., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.12.015 · Cited by 80
Self-citationArmstrong, A. J., Lin, P., Higano, C. S., Sternberg, C. N., Sonpavde, G., Tombal, B., Templeton, A. J., Fizazi, K., Phung, D., Wong, E. K., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy406 · Cited by 71
Maines, F., Caffo, O., Veccia, A., Trentin, C., Tortora, G., Galligioni, E., & Bria, E. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.07.013 · Cited by 71
Rasul, S., Hacker, M., Kretschmer‐Chott, E., Leisser, A., Grubmüller, B., Kramer, G., Shariat, S. F., Wadsak, W., Mitterhauser, M., Hartenbach, M., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04584-1 · Cited by 70
Oudard, S. M., Kramer, G., Caffo, O., Creppy, L., Loriot, Y., Hansen, S., Holmberg, M., Rolland, F., Machiels, J., & Krainer, M. (2014) · British Journal of Urology · doi:10.1111/bju.12845 · Cited by 67
Hofman, M. S., Emmett, L., Sandhu, S. K., Iravani, A., Joshua, A. M., Goh, J. C. H., Pattison, D. A., Tan, T. H., Kirkwood, I. D., Ng, S. S. W., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.5500 · Cited by 64
Lavaud, P., Gravis, G., Foulon, S., Joly, F., Oudard, S., Priou, F., Latorzeff, I., Mourey, L., Soulié, M., Delva, R., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.09.022 · Cited by 63 · cited 1×
“A retrospective analysis (62) of the GETUG-AFU15 phase 3 trial comparing docetaxel and ADT to ADT alone for mCSPC examined the efficacy of docetaxel re-introduction for mCRPC following docetaxel treatment in the mCSPC setting.”
MethodBuonerba, C., Ferro, M., Dolce, P., Crocetto, F., Verde, A., Lucarelli, G. T., Scafuri, L., Facchini, S., Vaia, A., Marinelli, A., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102992 · Cited by 55
Azad, A., Leibowitz‐Amit, R., Eigl, B. J., Lester, R. E., Wells, J. C., Murray, R. N., Kollmannsberger, C., Heng, D. Y. C., Joshua, A. M., & Chi, K. N. (2014) · The Prostate · doi:10.1002/pros.22872 · Cited by 54
Self-citationOh, W. K., Cheng, W. Y., Miao, R., Vekeman, F., Gauthier‐Loiselle, M., Duh, M. S., Drea, E., & Szatrowski, T. P. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.08.002 · Cited by 52
Shore, N. D., Saltzstein, D. R., SIEBER, P. R., Mehlhaff, B. A., Gervasi, L., Phillips, J. L., Wong, Y., Pei, H., & McGowan, T. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.07.017 · Cited by 47
Androgen receptor variant-driven prostate cancer II: advances in clinical investigation
Brown, L. C., Lu, C., Antonarakis, E. S., Luo, J., & Armstrong, A. J. (2020) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-0215-5 · Cited by 30
Nadal, R., Tsai, H., Sinibaldi, V. J., Paller, C. J., Antonarakis, E. S., Denmeade, S. R., Carducci, M. A., & Eisenberger, M. A. (2015) · The Prostate · doi:10.1002/pros.23141 · Cited by 24
Agarwal, N., Chowdhury, S., Bjartell, A. S., Chung, B. H., Gomes, A. J., Given, R. W., Soto, Á. J., Merseburger, A. S., Özgüroğlu, M., Uemura, H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.6_suppl.82 · Cited by 13
Self-citationManagement algorithms for metastatic prostate cancer
Malone, S. C., Shayegan, B., Basappa, N. S., Chi, K., Conter, H. J., Hamilton, R. J., Hotte, S. J., Saad, F., So, A., Park‐Wyllie, L. Y., et al. (2019) · Canadian Urological Association Journal · doi:10.5489/cuaj.5840 · Cited by 12
Self-citationChi, K. N., Taavitsainen, S., Iqbal, N., Ferrario, C., Ong, M., Wadhwa, D., Hotte, S. J., Lo, G. K., Tran, B., Azad, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.5003 · Cited by 3
Self-citation
Research works printed but not linked: 2
- [35]Khalaf DJ Annala M Taavitsainen S Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol 2019; 20: 1730- 9. 10.1016/S1470-2045(19)30688-6 31727538 · DOI · Paper page
- [49]Beer TM Armstrong AJ Rathkopf D Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol 2017; 71: 151- 4. 10.1016/j.eururo.2016.07.032 27477525 PMC5570461 · DOI · Paper page
Cited by
McManus, H. D., Dorff, T., Morgans, A. K., Sartor, O., Shore, N., & Armstrong, A. J. (2025) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-024-00906-z · Cited by 32
Zhou, T. T., Qin, S., Xu, W., Tang, S., Chen, G., Li, S., Hou, J., Gao, X., Shi, G., Sun, Z., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34512 · Cited by 9
Almeida, L. S., Megías, I. G., Etchebehere, E., Terán, A. K. C., Herrmann, K., Giammarile, F., Treglia, G., & Bolton, R. C. D. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06932-2 · Cited by 9
Teppala, S., Scuffham, P., & Tuffaha, H. (2024) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462324000011 · Cited by 8
Stenzl, A., Armstrong, A. J., Sboner, A., Ghith, J., Serfass, L., Bland, C. S., Schijvenaars, B. J. A., & Sternberg, C. N. (2024) · European Urology Focus · doi:10.1016/j.euf.2024.05.022 · Cited by 7
Metadata
- Authors
- Maurice Dror, C., Chi, K. N., & Khalaf, D. J.
- Affiliations
- BC Cancer Agency (CA)
- Corresponding author
- Khalaf, Daniel J.
- Venue
- Translational Andrology and Urology
- Publisher
- AME Publishing Company
- Published
- 2021-10
- Volume
- 10
- Issue
- 10
- Pages
- 3931-3945
- ISSN
- 2223-4683 (ISSN-L)
- 2223-4691
- PMC
- PMC8575566
- OpenAlex
- W3154460154
- Cited by
- 14
- References
- 84
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 6 · 2023: 2 · 2022: 1
- FWCI
- 0.36
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Translational Andrology and Urology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Prostate Cancer Foundation
- Pfizer
- Sanofi
- Astellas Pharma
- Daiichi Sankyo Europe
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- metastatic castration-resistant prostate cancer, treatment sequencing, treatment selection, androgen receptor pathway inhibitors, docetaxel, radium-223, immunotherapy, taxane-based chemotherapy, PARP inhibitors, PSMA-targeted therapy, predictive biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.